News & Announcements

PepLock now has a website of its own: peplock.au Technology, applications, FAQ and more.

Biotome has filed an international patent application elating to Peplock, its surface-binding peptide platform for stable biomolecule immobilisation on solid surfaces.

Biotome has just completed its first feasibility study for a peptide-based lateral flow device targeting CagA-positive H. pylori—and the results exceeded expectations.

Perth biotech awarded prestigious Future Health Research and Innovation (FHRI) Fund Innovation Seed Fund grant to develop a first-trimester blood test that could prevent hundreds of preeclampsia cases annually in Western Australia and thousands worldwide.

This study employed peptide microarray technology (Carmona 2015) to identify highly specific linear B-cell epitopes of the SARS-CoV-2 Spike protein that can distinguish between SARS-CoV-2 infection and pre-existing immunity to seasonal coronaviruses.

Thursday, August 25th, 2022 - Perth, Australia: Biotome has been granted US Patent No. 11,401,308 covering the use of peptides that can detect CagA+ Helicobacter pylori infection for use in diagnostics. Diagnostics using these peptides can identify individuals with carcinogenic CagA+ H. pylori infection, which is a major risk factor for developing stomach cancer. The patented peptides offer significant advantages over existing antigen-based methods as they target specific a

Perth, Australia – May 4, 2021 - Precision diagnostics company Biotome Pty Ltd has entered into a technology partnership with Cardea Bio Inc , a global leader in nanoelectronics manufacturing and the only mass-producer of graphene-based biological transistors. Through Biotome joining Cardea’s Innovation Partnership Program, the companies can work together to leverage Cardea’s proprietary Cardean Transistor™ technology for the development of electrochemical biosensors for pr